Medication that Reduces Cholesterol by Preventing the body's Production of Cholesterol
Received Date: Apr 03, 2023 / Published Date: Apr 27, 2023
Abstract
The Smith-Lemli-Opitz syndrome (SLOS) is a multiple malformation/mental retardation syndrome caused by a deficiency of the enzyme 7 dehydrocholesterol Δ7-reductase. This enzyme converts 7-dehydrocholesterol (7-DHC) to cholesterol in the last step in cholesterol biosynthesis. The pathology of this condition may result from two different factors: the deficiency of cholesterol itself and/or the accumulation of precursor sterols such as 7-DHC. Although cholesterol synthesis is defective in cultured SLOS cells, to date there has been no evidence of decreased whole body cholesterol synthesis in SLOS and only incomplete information on the synthesis of 7-DHC and bile acids. In this first report of the sterol balance in SLOS, we measured the synthesis of cholesterol, other sterols, and bile acids in eight SLOS subjects and six normal children. The diets were very low in cholesterol content and precisely controlled. Cholesterol synthesis in SLOS subjects was significantly reduced when compared with control subjects (8.6 vs. 19.6 mg/kg per day, respectively, P < 0.002).
Citation: Tachiura Y (2023) Medication that Reduces Cholesterol by Preventingthe body's Production of Cholesterol. J Pharmacokinet Exp Ther 7: 174. Doi: 10.4172/jpet.1000174
Copyright: © 2023 Tachiura Y. This is an open-access article distributed underthe terms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.
Share This Article
黑料网 Journals
Article Tools
Article Usage
- Total views: 1047
- [From(publication date): 0-2023 - Nov 23, 2024]
- Breakdown by view type
- HTML page views: 952
- PDF downloads: 95